2013 American Society of Hematology Annual Meeting*

December 7-10, 2013; New Orleans, Louisiana
CCO’s Independent Conference Coverage of the 2013 American Society of Hematology annual meeting includes Capsule Summaries of key studies plus expert analyses of new clinical trial findings with downloadable highlights slidesets. Topics include chronic lymphocytic leukemia and other B-cell malignancies, chronic myeloid leukemia, myelodysplastic syndromes and acute leukemias, and multiple myeloma.

Myelodysplastic Syndromes and Acute Leukemias


In this phase II study, the combination regimen was well tolerated, producing no grade 3/4 treatment-related adverse events.

Released: December 13, 2013

In this individual patient data meta-analysis of 5 clinical trials, gemtuzumab ozogamicin reduced relapse risk improving survival in patients with more favorable cytogenetics.

Released: December 14, 2013

ARRY-614 appears effective in both newly diagnosed patients with MDS and those previously treated with a hypomethylating agent.

Released: December 11, 2013

Cytogenetic abnormalities at the onset of AZA treatment in patients with high-risk MDS were predictive of survival but generally not cytogenetic response, and cytogenetic response had no effect on outcome.

Released: December 11, 2013

An improved safety profile was observed with lower-dose quizartinib vs higher doses in a previous study, specifically with lowering of QT prolongation rate, while achieving an equivalent bridging of patients to HSCT.

Released: December 14, 2013

Results of this randomized phase II trial demonstrate comparable efficacy and pharmacodynamics for 60- and 90-mg/m2 doses and an acceptable toxicity profile.

Released: December 14, 2013

Molecular analyses of patient samples obtained before and after diagnosis of therapy-related AML and therapy-related MDS provide a model to explain the poor chemotherapy response and excess TP53 mutations typically associated with this disease.

Released: December 15, 2013

In this phase I/II study of elderly patients with very poor cytogenetic factors (eg, del[5q], complex karyotype), 46% achieved CR with most responders also achieving cytogenetic response; however, median DFS was only 6 months.

Released: December 14, 2013

In this pilot study, extreme adverse events, including cytokine secretion and ferritin elevation, were observed in 25% of patients who received the CAR-expressing CTL019 T-cell infusion but were easily resolved with a single dose of tocilizumab.

Released: December 10, 2013

A phase I study of CD19-targeted T-cell therapy demonstrated CR rates > 75% in patients with minimal residual disease or morphologic residual disease with most eligible patients undergoing subsequent allo-SCT.

Released: December 13, 2013
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Celgene Corporation
Genentech BioOncology
Gilead Sciences
Takeda Oncology
Novartis Oncology
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?